Neurontin® is the brand name for the drug gabapentin and is a widely prescribed anti-convulsant approved by the FDA for the treatment of epilepsy.

Warner-Lambert Company ("Warner") has manufactured and sold the brand name prescription drug Neurontin® since its approval by the FDA on December 30, 1993. Warner marketed Neurontin® through its Parke-Davis division. Warner was acquired by Pfizer in June of 2000 and is presently a wholly owned subsidiary of Pfizer.

Warner was the owner of two patents related to Neurontin® which have since expired. These included a patent for the anhydrous compound gabapentin, which expired in 1998, and a patent covering the use of gabapentin to treat epilepsy which expired on January 16, 2000.

Neurontin® has been an extremely profitable pharmaceutical for Warner and subsequently for Pfizer. Neurontin® generated in excess of $1.3 billion in worldwide revenues in 2000, a substantial portion of which was derived from sales within the United States. Pfizer reported Neurontin® sales of $432 million for the last quarter of 2000 and sales of $812 million for the first two quarters of 2001.

If you believe you have been injured by Neurontin please contact us at neurontin@toxicdiscovery.com